Exhibition Summary Report: Yichang Tianrui Biopharm Co., Ltd successful attented CPHI Frankurt 2025

From 28th to 30th, Oct, Yichang Tranrui Biopharm Co., Ltd., a wholly-owned subsidiary of Humanwell Pharmaceutical Group, successfully participated in CPHI Frankfurt 2025, Germany. Our delegation, led by Mr. Lv, General Manager; Mr. Cai, Sales Director, engaged with the global pharmaceutical community to present our capabilities and explore new business opportunities. This report summarizes our key achievements and insights from the event.

We effectively communicated our position as a wholly-owned subsidiary of Humanwell Group, leveraging its global leadership in anesthesia and analgesia to build immediate credibility and trust. Significant interest was generated by our modern cGMP-compliant facilities and advanced technical platforms, including high-pressure hydrogenation and lyophilization. The successful completion of our $112 million Phase I investment, with 2 operational GMP workshops and 9 dedicated production lines, demonstrated our solid commercial production capacity.  Our diverse portfolio attracted high-quality leads: 

 Specialty APIs (e.g., Samidorphan L-Malate, Maribavir，Letermovir，Lumateperone Tosylate, Granisetron, Gadoxetate Disodium)

 Key Intermediates (e.g., 2-(2-amino-5-bromobenzoyl) pyridine, 7-ANCA)

Veterinary APIs (e.g., Alfaxalone, Fluralaner, Tiletamine Hydrochloride, Zolazepam Hydrochloride, Grapiprant)

 CDMO/CMO Services for HPAPIs and specialized processes.

The event provided valuable opportunities to connect with potential clients from key global markets. We observed a strong market demand for reliable suppliers of complex APIs and advanced intermediates, which aligns perfectly with our strategic focus. Numerous promising inquiries were received, particularly for our specialty APIs and custom manufacturing services.
Our participation at CPHI Frankfurt 2025, was a resounding success in establishing Yichang Tianrui Biopharm on the global stage. We have built a strong pipeline of potential collaborations and gained critical market intelligence.

We will now focus on a timely and structured follow-up to convert these opportunities into lasting partnerships.